Covid-19 roundup: Novavax plots EU vaccine shipments by end of year — report; Pfizer pledges medicines, equipment to India
With Novavax nearing a Phase III readout for its recombinant Covid-19 vaccine, the Maryland biotech will reportedly begin shipping commercial doses to the EU bloc as early as the end of 2021 with a formal agreement in the offing, Reuters reported.
Novavax will ship 200 million doses of its shot to the EU as part of a draft supply deal signed in December despite the fact the vaccine maker is still being plagued by production problems, the outlet said, citing an official familiar with the discussions.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.